Access to highly specific fluorescent reporter lines for imaging and Cre-driver lines for 4 7 5 functional manipulation is critical in our quest for understanding the roles of microglia in health 4 7 6 and disease. Previously generated lines efficiently target microglia, but also other cells of the 4 7 7 monophagocytic system (Wieghofer and Prinz, 2016) . Amongst a group of more recently 4 7 8 discovered microglia-specific genes, we chose targeting the Tmem119 gene to generate such 4 7 9 mouse lines (Bennett et al., 2016) . Specifically, we opted for a transgenic approach that 4 8 0 harnesses the Tmem119 locus to drive expression, while preserving endogenous Tmem119 4 8 1 expression. We designed a CRISPR/Cas9 strategy to insert EGFP or CreERT2, preceded by 4 8 2 ribosome-skipping peptide porcine teschovirus-1 polyprotein (P2A), into the stop codon of 4 8 3 murine Tmem119 ( Figure 1A ). Two founder lines were established for Tmem119-EGFP and 5 4 8 4 for Tmem119-CreERT2. 4 8 5
To determine whether the donor DNA was inserted correctly, a PCR-based approach was 4 8 6 used with primers spanning each junction. For both of the lines generated, specific 5' and 3' 4 8 7 junction PCR products were obtained, while no bands were observed with DNA from wildtype 4 8 8 animals ( Figure 1B ). This indicates specific insertion of the transgenes into the Tmem119 locus. 4 8 9
To further examine scarless integration at the junctions, PCR products from the CreERT2 line 4 9 0 were subject to Sanger sequencing covering the junctions. Both 5' and 3' sequencing traces show 4 9 1 endogenous bases corresponding to the WT sequence in intron 1 and the 3' UTR ( Figure 1C , D).
Additional sequencing confirmed absence of mutations across the entire targeted allele in both 4 9 3 lines. Together, these results confirm the generation of Tmem119-EGFP and Tmem119-CreERT2 4 9 4 lines. 4 9 5
While the function of endogenous Tmem119 is currently unknown, both its temporally 4 9 6 distinct pattern and high expression level suggest functional importance of this gene (Bennett et  4  9  7 al., 2016). We thus designed a knock-in approach with the objective of leaving endogenous 4 9 8 expression intact. To test whether Tmem119 expression is actually unaffected, we quantified 4 9 9
Tmem119 transcript levels in the Tmem119-EGFP line by qPCR. Examination of Tmem119 5 0 0 expression in WT and Tmem119-EGFP +/-mice revealed that transcript levels are comparable 5 0 1 between genotypes ( Figure 1E , WT median 0.9717, n=4, EGFP +/-median 0.9306, n=6, p= 5 0 2 0.5667 a ). We further examined TMEM119 protein expression using immunofluorescence and 5 0 3 found no difference between wildtype and Tmem119-EGFP +/-knock-in mice ( Figure 1F -G, WT 5 0 4 median 0.9835, n=4, EGFP +/-median 0.117, n=4, p=0.20 b ) Together, these data support the 5 0 5
conclusion that Tmem119 knock-in mice were generated with precision. 5 0 6
To further test whether the genetic engineering could affect the properties of microglia, 5 0 7
we examined basic morphological features of reconstructed immunostained microglia in 5 0 8
wildtype and Tmem119-EGFP +/-knock-in mice ( Figure 1H -I). Using this approach, we 5 0 9 determined that the cell body area ( Figure 1J Microglia populate the parenchyma in virtually all regions across the brain. To determine 5 2 0 the extent of EGFP expression in the newly generated Tmem119-EGFP line, we used confocal 5 2 1 microscopy on brain slices. Native EGFP fluorescence and antibody-enhanced signal were 5 2 2 visible across the brain in sagittal brain sections prepared from postnatal day 25 (P25) EGFP+/-5 2 3 mice ( Figure 2A ). To further assess whether EGFP is expressed in microglia, 5 2 4 immunofluorescence labeling of the endogenous microglia proteins IBA1 and TMEM119 was 5 2 5 employed. High power confocal microscopy shows that EGFP-positive cells in the parenchyma 5 2 6 are IBA1 and TMEM119-positive ( Figure 2B -E). Completion and fidelity of expression were 5 2 7
further assessed quantitatively in several brain regions. We found that 96.1 ± 2.0 % of the EGFP-5 2 8 expressing cells in the somatosensory cortex are IBA-1 expressing microglia and 98.2 ± 3.3 % of 5 2 9
IBA1-positive cells in this region are labeled by EGFP (Table 1) . In the striatum, 99.2 ± 2.1 % of 5 3 0 the cells labeled with EGFP were IBA1-expressing and 97.2 ± 1.8 % of IBA1-positive cells 5 3 1 displayed EGFP fluorescence. Labeling of microglia in the thalamus and hippocampus was 98.5 5 3 2 ± 0.8 % and 98.9 ± 1.9 % complete and 96.9 ± 2.3 % and 98.5 ± 3.5 % specific, respectively. To ( Figure 2K ) expressed EGFP ( Figure 2N ). In addition, to more comprehensively assess 5 3 7 specificity of EGFP expression, we immunostained oligodendrocytes, neurons, and astrocytes. 5 3 8
We found no evidence for expression of EGFP in these major CNS celltypes ( Figure 2O -Q). 5 3 9
Together, these data indicate highly complete and specific labeling of parenchymal microglia in 5 4 0 the Tmem119-EGFP reporter line. Figure 3A , B) 5 4 9 nor choroid plexus macrophages express EGFP ( Figure 3C , D). Adjacent microglia were clearly labeled with EGFP. 5 5 6
To further assess the specificity of EGFP expression in microglia beyond anatomical 5 5 7
location-based immunofluorescence analysis, we used flow cytometry ( Figure 3G-I Microglia populate the brain during early embryonic development (Ginhoux et al., 2010) .
Tmem119 mRNA is expressed throughout microglial development, but antibody-based methods 5 6 7 currently consistently label TMEM119 only as of later postnatal stages, typically postnatal day 5 6 8 14 (P14) and later (Bennett et al., 2016) . This makes it difficult to identify and discern microglia 5 6 9 from other monocytes at earlier time points. To determine whether the Tmem119-EGFP line 5 7 0 would specifically label microglia at early postnatal stages, we carried out immunofluorescence 5 7 1 microscopy at postnatal days 1, 3, and 6. EGFP expression in IBA1-positive cells was readily 5 7 2 observed in several regions examined, suggesting translation of Tmem119-P2A-EGFP transcript 5 7 3 at this stage ( Figure 4A-L) . Surprisingly, we also found EGFP expression associated with blood 5 7 4 vessels of P1 mice ( Figure 4A-C Figure 5A ). We administered tamoxifen daily for 3, 5 8 4 5, or 10 days to adult mice and 3 days to postnatal day 2 (P2) pups, and compared recombination 5 8 5 efficiency and fidelity for these different paradigms ( Figure 5A ). The mice were sacrificed 9-10 5 8 6 days after the last dose and subjected to immunofluorescence staining. High power images from 5 8 7
confocal microscopy showed tdTomato-labeling of IBA1-expressing microglia in mice that Assessment of the completeness of labeling as the ratio of tdTomato + IBA1 + -double positive 5 9 2 microglia (tdT + IBA1 + ) to all parenchymal microglia (IBA1 + ) revealed very high efficiency of 5 9 3 recombination ( Figure 5K ). Similarly, we examined the fidelity of labeling which represents the 5 9 4 fraction of actual parenchymal microglia (tdT + IBA1 + ) amongst all tdTomato-labeled cells (tdT + ) 5 9 5 in different parenchymal regions, and found high specificity close to 100 percent ( Figure 5L ). Of 5 9 6 note, increasing the days of tamoxifen administered to mice appeared to increase the fraction of 5 9 7 microglia undergoing recombination. At the same time, prolonged administration of tamoxifen 5 9 8 correlated with slightly reduced fidelity ( Figure 5K -L). We further sought to assess the 5 9 9 specificity of tdTomato expression using flow cytometry. Among a total of 1690 6 0 0 CD11b + CD45int/hi cells in the CNS, 33 were positive for tdTomato, indicating minimal, yet 6 0 1 nonzero, expression in non-microglial myeloid cells. 6 0 2
The flow cytometry data revealed that recombination was largely, but not 100 percent 6 0 3 specific. Furthermore, when examining the sections, we noticed some tdTomato fluorescence 6 0 4 that did not appear to be associated with parenchymal microglia. To explore the nature of this 6 0 5 ectopic fluorescence in this dosing paradigm, we imaged cells in the choroid plexus ( Figure 5N -6 0 6 P) as well as cells in the cortex, which were immunostained for the endothelial cell marker CD31 6 0 7
( Figure 5Q -S). In the choroid plexus, there was very weak tdTomato fluorescence and most 6 0 8 IBA1-positive macrophages did not express tdTomato ( Figure 5N -P). In the cortex, high power 6 0 9
confocal micrographs showed that the tdTomato and the CD31-immunolabeling signal were 6 1 0 largely separate, with some tdTomato overlap with a larger CD31-positive blood vessel ( Together, these data indicate that the Tmem119-CreERT2 line can be used to conditionally 6 1 4 control gene expression in adult and early postnatal microglia with good specificity.
Characterization of transgene expression in monocytes from Tmem119 knock-in mice 6 1 7
Monocytes infiltrate the brain and contribute to pathology in a number of brain disorders. 6 1 8
Currently widely used transgenic microglia lines also target monocytes in addition to microglia 6 1 9
and cannot readily distinguish the two cell types, thus hampering unequivocal attribution of 6 2 0 microglia function in these disorders. To assess the utility of Tmem119 knock-in mice for 6 2 1
investigating microglia in models of CNS disorders, we isolated blood monocytes and examined 6 2 2 transgene expression ( Figure 6A ). Using flow cytometry on white blood cells isolated from 6 2 3 control or Tmem119-EGFP +/-mice, we did not detect any EGFP-expression ( Figure 6B -C). To 6 2 4 further determine whether Tmem119-CreERT2 +/-mice display recombination in monocytes, we 6 2 5 administered tamoxifen and sacrificed the mice for analysis 7 days after the last dose (Figure 6 2 6 6D). Using flow cytometry on white blood cells, we found that about 3 percent of CD45 + cells 6 2 7 expressed tdTomato ( Figure 6E -F). This suggests that there is a low level of CreERT2 activity in 6 2 8
Tmem119-CreERT mice. Together, these data indicate high applicability of Tmem119-EGFP 6 2 9 mice and good applicability of Tmem119-CreERT2 mice to the study of brain disorders with 6 3 0 potential monocyte contribution. In this study, we addressed the critical need for transgenic mouse lines that specifically 6 3 9 label or control microglia, but not other closely related cell types with overlapping signature 6 4 0 gene expression (Bennett et al., 2016; Wieghofer and Prinz, 2016; Haimon et al., 2018) . We 6 4 1 targeted the recently identified microglia-specific Tmem119 gene to knock in EGFP or 6 4 2
CreERT2. Multiple analyses confirm correct insertion of the transgenes, intact expression of 6 4 3 endogenous Tmem119, and normal basic morphology of microglia in the knock-in mice . Using 6 4 4 immunofluorescence and flow cytometry approaches, we demonstrate that EGFP is expressed in 6 4 5 microglia, but not other cells of the monophagocytic system defined anatomically and by 6 4 6 signature protein expression. Flow cytometry further shows that EGFP is almost exclusively 6 4 7 expressed in CD11b + CD45lo cells corresponding to microglia. We further provide evidence for 6 4 8 early postnatal expression of EGFP and activity of CreERT2 in microglia upon tamoxifen 6 4 9
administration. In addition, we show that blood monocytes do not express EGFP and display 6 5 0 minimal activity of CreERT2. Together, our findings indicate proper generation of the two 6 5 1 mouse lines, which are now readily available through a public repository (JAX#031823 for 6 5 2
Tmem119-EGFP and JAX#031820 for Tmem119-CreERT2). 6 5 3 TMEM119 is a single transmembrane protein that is highly expressed in microglia in the 6 5 4
brains of humans and mice (Bennett et al., 2016; Satoh et al., 2016) . In this study, we opted to 6 5 5 refrain from knocking Tmem119 out through insertion of EGFP or CreERT2 into the Tmem119 6 5 6
ORF and instead chose to preserve expression by using a polycistronic knock-in approach with 6 5 7 ribosomal skipping peptide P2A ( Figure 1A ). This was primarily motivated by the high 6 5 8 expression levels of Tmem119, conservation of expression in microglia across species, and 6 5 9 potential developmental regulation patterns, all of which suggest the importance of this gene. Examination of EGFP expression and co-expression analysis with TMEM119, IBA1, and 6 6 6 CD163 revealed that EGFP labels only parenchymal microglia (Figures 2 and 3 ). Identification 6 6 7 of these cells was possible by direct observation of EGFP fluorescence as well as by analysis of 6 6 8 immunostaining-enhanced tissue sections, supporting the conclusion that EGFP expression levels 6 6 9 are robust. Flow cytometry analysis further showed expression of EGFP in virtually all 6 7 0 CD11b + CD45lo microglia ( Figure 2N ) and a minor fraction of 6.9 percent (153/2212) of 6 7 1 CD11b + CD45int/hi cells ( Figure 3G-I ). This reflects that Tmem119 expression is highly 6 7 2 selective, but not completely restricted to microglia, which has been observed in recent single-6 7 3 cell sequencing studies (Li et al., 2019 ). An interesting observation was the expression of EGFP 6 7 4
at early postnatal time points in microglia (P1, P3, and P6), but also endothelial cells of blood 6 7 5 vessels at P1 (Figure 4 ). This is interesting for two reasons. First, it suggests that Tmem119 is 6 7 6 initially expressed in microglia and endothelial cells and only becomes a specific microglia 6 7 7 marker during early postnatal development, presumably by selective up-and downregulation of 6 7 8 expression in microglia and endothelial cells, respectively. Second, translational processing of 6 7 9
Tmem119 transcript appears to stand in opposition to a previous report showing that, while RNA 6 8 0 sequencing detects Tmem119 mRNA throughout development, immunostaining only identifies 6 8 1 TMEM119 protein at later postnatal stages (Bennett et al., 2016 
EGFP discerns parenchymal microglia from other brain macrophages. A, IBA1 labels 7 9 5 meningeal macrophages and parenchymal microglia from the region indicate with a dashed box 7 9 6 in figure 2A . B, EGFP labels only parenchymal macrophages (open arrowheads), but not 7 9 7 meningeal IBA1-positive macrophages (closed arrowheads). Diffuse fluorescence is associated 7 9 8 with pia. ECIC, external cortex of inferior colliculus; Cer, cerebellum. Scale bar 100 µm. C and 7 9 9 D, Choroid plexus IBA1 + macrophages (closed arrowheads) from the region boxed in figure Hippocampus. CPu = Caudate-Putamen. Ctx = Cortex. N=2 mice for 3 days, 3 mice each for 5 8 3 3
and 10 days of TAM in adults, and 3 mice for 3 days administration at P2 = postnatal day 2. 8 3 4
Floating bars = min to max, line at mean. 
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